Literature DB >> 31563334

The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease.

Inga Soveri1, Johan Mölne2, Fredrik Uhlin3, Thomas Nilsson4, Christian Kjellman5, Elisabeth Sonesson5, Mårten Segelmark6.   

Abstract

In anti-glomerular basement membrane (anti-GBM) disease, IgG class autoantibodies induce rapidly progressive glomerulonephritis. Regrettably, many patients are diagnosed at a late stage when even intensive conventional treatment fails to restore renal function The endopeptidase IdeS (Immunoglobulin G degrading enzyme of Streptococcus pyogenes) (imliflidase) rapidly cleaves all human IgG subclasses into F(ab')2 and Fc fragments. We received permission to treat three patients with refractory anti-GBM nephritis without pulmonary involvement on a compassionate basis. All patients were dialysis-dependent for days or weeks when treated, and all had high levels of circulating anti-GBM despite plasma exchange. A single dose of IdeS led to complete clearance of circulating anti-GBM antibodies in all three patients. After about a week, all rebounded but the rebounds were easily managed by plasma exchange in two of three cases. Renal histology demonstrated severe crescentic glomerulonephritis with acute but mainly chronic changes. Staining for the Fc fragment was negative in all while Fab was positive in two patients. Unfortunately, none of the patients regained independent renal function. Thus, treatment with IdeS led to rapid clearance of circulating and kidney bound anti-GBM antibodies. The clinical utility, dosing and usage to preserve renal function remain to be determined.
Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IdeS; IgG; PLEX; anti-GBM disease

Year:  2019        PMID: 31563334     DOI: 10.1016/j.kint.2019.06.019

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

Review 1.  Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation.

Authors:  Edmund Huang; Angela Q Maldonado; Christian Kjellman; Stanley C Jordan
Journal:  Am J Transplant       Date:  2021-09-13       Impact factor: 9.369

2.  Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy.

Authors:  Xinfang Xie; Jingyi Li; Pan Liu; Manliu Wang; Li Gao; Feng Wan; Jicheng Lv; Hong Zhang; Jing Jin
Journal:  J Am Soc Nephrol       Date:  2022-02-16       Impact factor: 14.978

3.  Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study.

Authors:  Fredrik Uhlin; Wladimir Szpirt; Andreas Kronbichler; Annette Bruchfeld; Inga Soveri; Lionel Rostaing; Eric Daugas; Arnaud Lionet; Nassim Kamar; Cédric Rafat; Marek Mysliveček; Vladimír Tesař; Anders Fernström; Christian Kjellman; Charlotte Elfving; Stephen McAdoo; Johan Mölne; Ingeborg Bajema; Elisabeth Sonesson; Mårten Segelmark
Journal:  J Am Soc Nephrol       Date:  2022-03-08       Impact factor: 14.978

Review 4.  New therapeutic perspectives for IgA nephropathy in children.

Authors:  Alexandra Cambier; Patrick J Gleeson; Héloise Flament; Marie-Bénédicte Le Stang; Renato C Monteiro
Journal:  Pediatr Nephrol       Date:  2020-02-10       Impact factor: 3.714

Review 5.  Epidemiology, Impact, and Management Strategies of Anti-Glomerular Basement Membrane Disease.

Authors:  Muhammad Asim; Mohammed Akhtar
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-04-07

Review 6.  The glomerular crescent: triggers, evolution, resolution, and implications for therapy.

Authors:  Lidia Anguiano; Renate Kain; Hans-Joachim Anders
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-05       Impact factor: 3.416

Review 7.  A Comprehensive Overview of the Clinical Relevance and Treatment Options for Antibody-mediated Rejection Associated With Non-HLA Antibodies.

Authors:  Tineke Kardol-Hoefnagel; Henny G Otten
Journal:  Transplantation       Date:  2021-07-01       Impact factor: 5.385

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.